XW043H5
Introduction Central Vein to New Technology Group 5 with Tocilizumab, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | 4 Central Vein |
| Approach | 3 Percutaneous |
| Device | H Tocilizumab |
| Qualifier | 5 New Technology Group 5 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Central Vein
Central veins, including the vena cavae and other large-caliber vessels near the heart, provide access for substances that require rapid dilution, higher infusion volumes, or delivery closer to central circulation than a peripheral vein allows. Introduction procedures coded here under New Technology reflect administration of a novel agent through this central route, which is often chosen when a substance is irritating to smaller vessels or needs to reach systemic circulation quickly and at high concentration. Central venous access typically requires a dedicated catheter placed under imaging or landmark guidance, and the procedure carries different risks, including central line infection, compared with peripheral administration. Coding accuracy depends on documenting that central rather than peripheral venous access was used for the introduced substance.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: Tocilizumab
Tocilizumab is a monoclonal antibody that inhibits the interleukin-6 receptor, dampening inflammatory signaling implicated in conditions such as rheumatoid arthritis, cytokine release syndrome, and severe COVID-19-associated inflammation. It shares its IL-6 receptor-blocking target with sarilumab but is a separately coded agent with its own dosing and indication profile, distinct from the complement- or B-cell-targeted therapies elsewhere in this list.
Qualifier: New Technology Group 5
Group 5 designates technologies recognized under the New Technology section for the 2018-2019 update, sitting in the middle of the section's early expansion years. The qualifier's only job is to timestamp the code to its approval cohort; the actual clinical substance is defined by the other axis positions in the same code. Confusion most often arises with the neighboring Group 4 and Group 6 values, which cover adjacent years.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.